BioXcel Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

BioXcel Therapeutics, Inc. (BTAI) announced that Dr. Vimal Mehta, the Founder and CEO, will present at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 3:30 PM ET. The event will showcase the company's innovative use of artificial intelligence in developing therapies aimed at neuroscience and immuno-oncology. A live webcast of the presentation will be available on the company's website, with an archive accessible for 30 days post-event. BioXcel is known for its drug re-innovation approach, focusing on advanced clinical programs like BXCL501 and BXCL701.

NEW HAVEN, Conn., May 28, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the Jefferies Virtual Healthcare Conference.

Presentation Details:
Event: Jefferies Virtual Healthcare Conference
Date: Thursday, June 4, 2020
Time: 3:30 PM ET

A live webcast of the presentation and the accompanying presentation materials will be accessible through the Investors section of the Company's website at www.bioxceltherapeutics.com. Following the conference, the webcast will be archived on the Company’s website for 30 days.

About BioXcel Therapeutics, Inc.:

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit www.bioxceltherapeutics.com.

Contact Information:

BioXcel Therapeutics, Inc.
www.bioxceltherapeutics.com

Investor Relations:
John Graziano
jgraziano@troutgroup.com
1.646.378.2942

Media:
Julia Deutsch
jdeutsch@troutgroup.com
1.646.378.2967

FAQ

What is the date and time of BioXcel Therapeutics' presentation at the Jefferies Virtual Healthcare Conference?

BioXcel Therapeutics will present on June 4, 2020, at 3:30 PM ET.

Where can I watch the BioXcel Therapeutics presentation from the Jefferies Virtual Healthcare Conference?

The presentation can be accessed via a live webcast on BioXcel Therapeutics' website.

What are the key areas of research for BioXcel Therapeutics as mentioned in the press release?

BioXcel Therapeutics focuses on neuroscience and immuno-oncology using artificial intelligence.

What are the two advanced clinical programs of BioXcel Therapeutics?

The two advanced clinical programs are BXCL501 for neuropsychiatric agitation and BXCL701 for rare prostate cancer and pancreatic cancer.

How long will the webcast of BioXcel Therapeutics' presentation be available after the event?

The webcast will be archived on the company’s website for 30 days after the event.